Data Support Use of Novel Product with Enteral Feeding
NEWTON, Mass – October 8, 2015 - Alcresta®, a specialty pharmaceutical company focused on developing innovative enzyme-based products for gastrointestinal and rare diseases, today announced new clinical data highlighting the company’s technology and product, will be presented at the 29th Annual North American Cystic Fibrosis Conference (NACFC), being held Oct. 8-10, 2015 in Phoenix, Ariz.
Following is an overview of the data being presented at the conference:
- “Novel Immobilized iLipase Device (EFIC) Enhances the Nutritional Benefits of Enteral Feeding and Provides Greater Flexibility for Shorter Duration Feedings and Reduced Volumes” will highlight study results showing the use of EFIC in an animal model. This data will be presented by Greta Loring, senior director, new product planning, on Thursday, October 8, 2015 from 10 to 11:45 a.m. during the “Nutrition Research” session in Room 120D. The abstract will also be available as a poster (#557) in the exhibit hall on Thursday, October 8, 2015, from 11:50 a.m. to 1:50 p.m., and Saturday, October 10, 2015, from 7:30 a.m. to 8:45 a.m.
- “In-Line Digestive Enzyme Cartridge (EFIC), as a Part of Enteral Feeding, Facilitates Effective Fat Absorption and Increases Omega 3 Plasma Levels in Pig Model of Exocrine Pancreatic Insufficiency (EPI)” will provide the results after 12 days of enteral tube feeding using EFIC in an established porcine model of EPI. This data will be presented by Danica Grujic, senior director, pharmacology, on Friday, October 9, 2015 from 2:00 p.m. to 3:45 p.m. during the “Gastroenterology/Liver/Pancreas” session in Room 120D. The abstract will also be available as a poster (#563) in the exhibit hall on Thursday, October 8, 2015, from 11:50 a.m. to 1:50 p.m., and Saturday, October 10, 2015, from 7:30 a.m. to 8:45 a.m.
- “Long Term Positive Effects of G-tube Feeding with an In-line EFIC on the Tissue Levels of DHA and EPA in Pig Model of Exocrine Pancreatic Insufficiency (EPI)” will underscore the use of this in-line digestive enzyme cartridge in patients who are receiving enteral tube feeding. The poster will be available in the exhibit hall on Thursday, October 8, 2015, from 11:50 a.m. to 1:50 p.m. and Friday, October 9, 2015 from 7:30 a.m. to 8:45 a.m.
About the NACFC
The North American Cystic Fibrosis Conference serves as a collaborative forum to advance research for the treatment and cure of CF, and is an ideal opportunity to receive state-of-the-art continuing medical education and learn about the latest products and services in CF care. The educational elements of the meeting program are targeted to physicians, nurses, research scientists, respiratory therapists, physical therapists, nutritionists, social workers, and pharmacists to share the latest research and advances in CF. The meeting is held over three days with more than 60 concurrent sessions.
Alcresta is a specialty pharmaceutical company dedicated to developing and commercializing novel enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency, which results in malabsorption common in cystic fibrosis, digestive cancers, premature birth and other serious diseases. The company’s lead product, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral tube feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). The importance of long-chain polyunsaturated fatty acids like omega-3 is well documented across the full spectrum of patient care from infants to adults and individuals battling acute conditions or chronic diseases. The company’s platform is supported by the Alcresta team’s extensive experience in pharmaceutical and nutritional product development. Based in Newton, Mass., the company is backed by top- tier venture investors Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures. For more information, please visit www.alcresta.com.
Alcresta Pharmaceuticals, Inc. 617-431-3586